Psychotic symptoms in patients with borderline personality disorder: prevalence and clinical management

Psychotic symptoms in patients with borderline personality disorder: prevalence and clinical management

Schroeder, Katrina; Fisher, Helen L.b; Schäfer, Ingoa

Current Opinion in Psychiatry:
January 2013 – Volume 26 – Issue 1 – p 113–119
doi: 10.1097/YCO.0b013e32835a2ae7
PERSONALITY DISORDERS: Edited by Charles B. Pull and Aleksandar Janca

 

INTRODUCTION

Psychotic features in borderline personality disorder (BPD) are a long known phenomenon. As the name of the disorder signifies, it was originally introduced to describe patients who seemed to be on the border between neurosis and psychosis [1]. Although this concept has later been replaced by an operationalized diagnosis [2], psychotic symptoms have always been considered to be an important feature of BPD (e.g. [3,4,5]). Nevertheless, empirical evidence is scarce, partly because of conceptual difficulties. This article reviews the existing findings on the phenomenology and prevalence of psychotic symptoms in BPD. Moreover, we discuss variables potentially related to their appearance and give an overview of studies on their clinical management.

PHENOMENOLOGY AND DEFINITION

Psychotic symptoms in patients with BPD can broadly be divided into perceptual abnormalities and paranoid ideation, but there is currently no consensus on the phenomenology and severity of these experiences [5]. Both clinical concepts and current diagnostic systems fail to provide a framework for understanding these phenomena. This seems to be a major obstacle on the way to valid definitions. For instance, the only BPD criterion in DSM-IV [6] related to psychotic symptoms is transient, stress-related paranoid ideation. The criteria therefore do not account for other common symptoms, like hallucinations or longer-lasting paranoid episodes [5], and, in the proposed revision of the BPD criteria in DSM-V, even paranoid ideation will no longer be included [7].

A variety of vague terms like ‘quasi-psychotic thought’ [8] or ‘pseudo-hallucinations’ [9] have been used to describe paranoid ideation and perceptual abnormalities in BPD.

Box 1

Since Hagen first introduced the term ‘pseudo-hallucinations’ in 1868 [10], many attempts have been made to define these phenomena (for reviews see [9,11]). Common definitions suggest that pseudo-hallucinations are recognized as such by the individual, and that they can be distinguished from ‘real’ hallucinations by their quality and location. ‘Pseudo-hallucinations’ are usually assumed to be voices or ‘inner images with vivid liveliness’ which are experienced ‘inside of the head’, whereas ‘true’ hallucinations, found in schizophrenia and other psychotic disorders, typically in the form of auditory verbal hallucinations (AVH), are assumed to be perceived as coming from ‘outside’ of the individual [9,11]. Recent research, however, suggests that the nature of hallucinations in different populations is less clear [12,13,14,15]. For instance, Copolov et al.[15] found that about a third of patients with schizophrenia perceived auditory hallucinations as internal, the same number of patients perceived them as external, and the remaining as coming from both locations. Moreover, no association existed between hearing voices internally and ‘insight’ into their hallucinatory character. On the contrary, patients with dissociative disorders (e.g. [16]), Posttraumatic Stress Disorder (PTSD) (e.g. [17]), and even individuals without psychiatric disorders (e.g. [18]) experience auditory hallucinations that could be classified as ‘true’ hallucinations according to their location (i.e. outside the head) and content. Interestingly, the same pattern of brain activation has been found in psychotic and nonpsychotic individuals with AVH [19]. As a consequence, more research on the phenomenology of AVH in different populations is needed [13], but it has been argued that the term ‘pseudo-hallucinations’ should no longer be used, to prevent trivialization and promote adequate diagnosis and treatment of these phenomena [5,20].

PREVALENCE AND QUALITY OF PSYCHOTIC SYMPTOMS IN BORDERLINE PERSONALITY DISORDER

Remarkably few empirical studies have examined psychotic symptoms in BPD so far. The existing studies either focused on hallucinations [5,21–23], or both hallucinations and paranoid delusions [8,12,24–26]. Two early studies [21,22] found that auditory hallucinations were experienced by 21 and 54% of BPD patients respectively. Yee et al.[23] found AVH in 50 out of 171 patients with BPD (29%) using the Symptom-Checklist-90 (SCL-90; [27]) as a screening tool. Kingdon et al.[12] reported that 46% of a smaller sample of 33 patients with BPD reported AVH on the Psychotic Symptoms Rating Scale (PSYRATS; [28]), and 29% were found to have experienced paranoid delusions. Rates of psychotic symptoms in nonclinical populations of individuals with BPD, however, could be markedly lower [29].

Two studies using different versions of the Diagnostic Interview for Borderlines (DIB; [30,31]) tried to differentiate between quasi-psychotic and true psychotic symptoms according to the criteria of this instrument [8,25]. Zanarini et al.[8] examined 50 patients meeting the criteria for BPD according to DSM-III. Patients with a concomitant psychotic disorder were excluded. Patients’ experiences were judged as quasi-psychotic if they were transient (of less than 2 days’ duration), circumscribed (affecting not more than two areas of the patients’ life), or atypical of psychotic disorders (possibly reality-based or totally fantastic in content). Delusions and hallucinations that were prolonged, bizarre or stereotypic of psychotic disorders (Schneiderian first-rank symptoms or other gross departures from reality) were rated as true psychotic experiences. According to these definitions, 40% of the patients (N = 20) reported quasi-psychotic thought, 26% (N = 13) reported quasi-hallucinations, and 14% (N = 7) reported having experienced true psychotic thought, i.e. they had experienced a psychotic episode lasting 2 days or more anytime in their life.

Several studies compared the prevalence and quality of psychotic symptoms in patients with BPD with those in other diagnostic groups [5,12,25,32]. Kingdon et al.[12] administered the PSYRATS to 111 patients, of whom 59 met, in the Structured Clinical Interview for DSM-IV (SCID; [33]), the criteria for schizophrenia, 33 for BPD, and 19 for both disorders. Of patients with BPD only, 29% (N = 9) reported paranoid delusions, as compared with almost two-thirds of patients with schizophrenia (N = 36; 61%) and with both diagnoses (N = 12; 65%). Almost two-thirds (63%) of the sample also described experiencing auditory hallucinations. This was the case in about half (46%) of those with BPD, two-thirds (66%) of those with schizophrenia, and an even higher number (90%) of patients with both diagnoses. The authors found greater distress and more negative content of voices in patients with BPD alone as compared with the other groups; no differences were found with regard to conviction, frequency, or beliefs about the location of the auditory hallucinations.

In a recent study, Slotema et al.[5] used the PSYRATS to compare the characteristics of AVH in 38 BPD patients with known AVH with those of 51 patients with schizophrenia or schizoaffective disorder, and 66 individuals without a psychiatric diagnosis. Although BPD patients had higher scores on almost all items of the instrument as compared with nonpatients experiencing AVH, BPD patients’ AVH did not differ from those of patients with schizophrenia except for the item ‘disruption of life’, which was rated higher in patients with schizophrenia. In this study, the mean frequency of AVH in BPD patients was at least once per day for several minutes or more, and AVH were experienced inside the head in the majority of patients.

Although the DSM-IV criteria [6] suggest that psychotic symptoms in BPD are transient, studies examining the duration of symptoms came to contradicting results. Miller et al.[24] performed a chart review of psychotic symptoms (delusions, auditory, and visual hallucinations) in 92 inpatients with BPD. Twenty-seven percent (n = 25) were found to have had psychotic episodes, which typically lasted for many weeks. Similar findings have been reported in several case-series [20,23,26]. In the study by Slotema et al.[5], BPD patients had experienced AVH for a mean duration of 18 years on a daily basis. When patients’ level of distress was assessed (e.g. [5,12,23]), BPD patients with prolonged AVH perceived them as highly distressing.

ARE PSYCHOTIC SYMPTOMS RELATED TO COMORBID DISORDERS?

Patients with BPD frequently meet DSM-IV criteria for other mental disorders (e.g. [4]). It has therefore been suggested that comorbid psychotic symptoms could be related to psychiatric comorbidity rather than to BPD per se, but empirical evidence on this question is scarce. Two studies reported that longer-lasting psychotic episodes in patients with BPD were related to major depression or substance abuse [8,25]. In a study by Nishizono-Maher et al.[25] that compared patients with BPD, depression, or both disorders, psychotic symptoms seemed to be related to depression independently of BPD status. Findings of other studies did not support such a relationship (e.g. [24,34]). Benvenuti et al.[34] examined a sample of BPD patients with (N = 39) or without (N = 21) lifetime mood disorders using the Structured Clinical Interview for Psychotic Spectrum (SCI-PSY; [32]). In patients with comorbid mood disorders, manic features were correlated with different subdomains of the SCI-PSY, but only minor differences between the groups were observed.

Comorbid psychotic disorders could be an obvious explanation for longer-lasting psychotic episodes in patients with BPD. In the study by Kingdon et al.[12] 17% of 111 patients who had a diagnosis of BPD or schizophrenia received both diagnoses and bipolar spectrum diagnoses have been found in 6–15% of patients with BPD [35]. Conversely, in populations of patients with schizophrenia spectrum disorders, 5–18% have been shown to meet a diagnosis of BPD [36–38]. Most studies among clinical populations of patients with BPD, however, either explicitly excluded patients with psychotic disorders (e.g. [8,39,40]), or did not provide any information on this potential comorbidity, making inferences about potential relationships with psychotic symptoms difficult.

RELATIONSHIPS WITH CHILDHOOD TRAUMA

Research from populations other than BPD indicates that childhood trauma might play an important role in the later development of psychotic symptoms (for review see [41]). Using data from the National Comorbidity Survey Replication [42], Shevlin et al.[43] found that both rape and physical assault in childhood significantly predicted visual and auditory hallucinations later in life. Daalman et al.[18] reported that sexual and emotional abuse in childhood was significantly related to auditory hallucinations not only in patients with psychotic disorders but also in nonpsychotic individuals from the community. As for hallucinations, a number of well-designed studies robustly demonstrated associations between trauma exposure in childhood and delusional experiences in adulthood [41]. Childhood trauma is highly prevalent in patients with BPD, childhood sexual abuse alone being reported by 40–76% of patients (for review see [44]). Childhood emotional abuse, another type of trauma with a high risk of psychopathology later in life [45], is reported by up to 92% of patients with BPD [12,46,47]. Individuals with BPD experience more different types of childhood trauma, starting earlier in life, and continuing over longer periods of time than comparison groups [48,49]. Although it can be assumed that the same relationships between childhood trauma and psychotic symptoms exist in patients with BPD as in other groups, no studies on this question have been conducted so far.

In patients with BPD psychotic symptoms typically occur in reaction to stressful events (e.g. [20,23,50]). Their occurrence might therefore be moderated by further consequences of childhood trauma, namely high sensitivity to stress, and symptoms of PTSD. PTSD is present in 58–79% of patients with BPD [35,47], and the disorder can itself include psychotic symptoms [51,52], or could promote their appearance by enhancing the burden of stress in the individual concerned [53]. Glaser et al.[50] used a structured diary technique to compare relationships between daily-life stress and the occurrence of psychotic experiences in patients with BPD, cluster C personality disorder, psychotic disorders, and healthy controls. Although all patient groups experienced increases in psychotic experiences in relation to stress, patients with BPD displayed the strongest reactivity. Psychotic reactivity to stress was not limited to paranoia but involved a broader range of psychotic experiences, including also hallucinations.

CLINICAL MANAGEMENT OF PSYCHOTIC SYMPTOMS IN BORDERLINE PERSONALITY DISORDER

Clinical definitions of psychotic symptoms in patients with BPD suggest that they are ‘transient’ or ‘pseudo-psychotic’ [5,20]. Patients can be aware that clinicians have no common language for longer-lasting, more severe psychotic symptoms in BPD [20], and that these symptoms can be considered a diagnostic sign for schizophrenia or other psychotic disorders. In an attempt to avoid being considered ‘crazy’, patients may underreport psychotic symptoms [23]. Yet, as a prerequisite for adequate treatment planning, there is a need for systematic screening and assessment of psychotic symptoms in patients with BPD. Several instruments developed for psychotic populations have also been used in patients with BPD (e.g. [5,12,29,32]) and some have been reported to be reliable and valid also in this diagnostic group (e.g. [32]).

Several studies examined the use of antipsychotics, mainly olanzapine, in the treatment of patients with BPD (e.g. [54–58]). Most of these studies, however, focused on general symptoms of BPD as the main outcome and only a smaller number of trials also examined their efficacy on psychotic symptoms. In case-series and open studies, promising findings with regard to the reduction of psychotic symptoms were reported for clozapine [59–61], olanzapine [62,63], quetiapine [64,65], risperidone [66], palliperidone [67] and aripiprazole [68,69]. In a small controlled study [70] patients in the olanzapine group (N = 16) improved significantly more on the paranoia subscale and most other subscales of the SCL-90 as compared with patients receiving placebo (N = 9). Findings for the psychoticism subscale were not reported. In a larger study of the same group [71] psychotic symptoms were assessed more specifically using the Zanarini Rating Scale for BPD [72]. After 12 weeks of treatment, significantly greater reductions of the ‘paranoid ideation and dissociation’ scale compared with a placebo group (N = 153) were reported in patients receiving 5–10 mg olanzapine per day (N = 148, M = 6.7 mg), but not in patients receiving a fixed dose of 2.5 mg per day (N = 150). Another randomized controlled trial (RCT) [39] found no significant difference between patients treated for 12 weeks with 2.5–20 mg olanzapine per day (N = 155, M = 7.1 mg) and a control group (N = 159).

In a study by Nickel et al.[73] 52 patients with BPD were treated for 8 weeks with aripiprazole (N = 26, 15 mg per day) or placebo (N = 26). Patients receiving aripiprazole showed significantly greater reductions of almost all subscales of the brief symptom inventory (BSI) [74], including ‘paranoid thinking’ and ‘psychoticism’. A follow-up 18 months later showed that the improvements in the intervention group had further increased over time [68]. In a 12-week placebo-controlled study, no significant effect on psychotic symptoms rated on the Brief Psychiatric Rating Scale (BPRS) [75] was found in 60 BPD patients treated with either 40–200 mg ziprasidone per day (N = 30; M = 84.1 mg) or placebo [76]. In all four RCTs, patients with psychotic disorders had been excluded. All of these trials, however, share a number of shortcomings. None of them reported the percentage of patients with psychotic symptoms and all used subscales of general instruments rather than assessing psychotic symptoms in more detail. Nevertheless, the existing findings lend some support to the use of atypical antipsychotics in BPD patients with psychotic symptoms.

Although pharmacotherapy can be considered a useful adjunct of psychotherapy in patients with BPD, clinicians [77,78] and professional guidelines [79] emphasize the symptomatic nature of relief with medication. Given that psychotic symptoms in patients with BPD are often related to stress and acute emotional crises [20,23,50], it has been suggested that psychotherapy interventions addressing these crises should play a central role in the treatment of psychotic symptoms in BPD. Laddis [78] followed the concept that acute crisis in BPD often results from current perception of dependency and entrapment in a mistrusted relationship. In a pilot study, this author used a short intervention tailored to this hypothesis to treat 32 patients with BPD after admission to a crisis intervention unit. After two days, significantly greater improvements on the BPRS were reported for this group as compared with 26 controls with BPD treated in similar crisis stabilization units.

Patients suffering from both BPD and psychotic disorders seem to be a particularly vulnerable group with complex pathways to care [80] and a worse outcome as compared with patients with psychotic disorders alone [36]. Consequently, efforts have been made to offer specialized integrated treatment services for this group of patients. Gleeson et al.[81] evaluated an integrated early intervention program for young patients with co-occurring first-episode psychosis and BPD. In a pilot study, the combination of a specialist first-episode program for psychotic disorders with an early intervention program for BPD in young people (‘Helping Young People Early Programme’; [82]) was shown to be well tolerated, feasible and well accepted by patients. No comparable studies have been published for BPD patients with longer-lasting psychotic symptoms not suffering from a psychotic disorder, potentially representing the majority of BPD patients with psychotic symptoms. Given that AVH in this group are similar to those in patients with psychotic disorders in terms of phenomenology and cognitive responses to them [14,83], it might be fruitful to adapt cognitive-behavioural approaches for the treatment of persisting ‘positive symptoms’ in patients with schizophrenia and other psychotic disorders to the needs of patients with BPD [83].

CONCLUSION

Psychotic symptoms, especially hallucinations, are highly prevalent in patients with BPD. Recent studies suggest that hallucinations in BPD are similar to those in patients with psychotic disorders in terms of phenomenology, but their emotional impact seems to be even stronger in patients with BPD. Terms like ‘pseudo-psychotic’ or ‘quasi-psychotic’ symptoms are therefore misleading and should be avoided. Although symptoms could be called transient in the sense that they are not constantly present during the day, symptoms are present for long periods of time in a significant proportion of patients. Given the high prevalence of childhood trauma in patients with BPD and the relationships between childhood trauma and psychotic symptoms in other diagnostic groups, early life stress should receive more attention as a potential cause of psychotic symptoms in patients with BPD. More research is necessary on the role of psychiatric comorbidity, especially comorbid PTSD, as a cause of psychotic symptoms, or as a mediator between early life stress and psychotic symptoms in this diagnostic group. Atypical antipsychotics are beneficial in the treatment of psychotic symptoms in some patients, but more pharmacological studies focussing explicitly on psychosis in BPD are needed. Psychotic symptoms should be routinely assessed and it could be beneficial to adapt psychotherapy approaches with proven efficacy in other diagnostic groups for use in patients with BPD.

Acknowledgements

K.S. is supported by an intramural research program of the University Medical Center Hamburg-Eppendorf.

H.L.F. is supported by a Population Health Scientist fellowship from the UK Medical Research Council.

Conflicts of interest

There are no conflicts of interest.

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

▪ of special interest

▪▪ of outstanding interest

Additional references related to this topic can also be found in the Current World Literature section in this issue (p. 132).

REFERENCES

1. Stern A. Psychoanalytic investigation of and therapy in the border line group of neuroses. Psychoanal Q 1938; 7:467–489.

2. Pope HG, Jonas JM, Hudson JI, et al. The validity of DSM-III borderline personality disorder. A phenomenologic, family history, treatment response, and long-term follow-up study. Arch Gen Psychiatry 1983; 40:23–30.

3. Skodol AE, Oldham JM. Assessment and diagnosis of borderline personality disorder. Hosp Community Psychiatry 1991; 42:1021–1028.

4. Skodol AE, Gunderson JG, Pfohl B, et al. The borderline diagnosis I: psychopathology, comorbidity, and personality structure. Biol Psychiatry 2002; 51:936–950.

5▪. Slotema CW, Daalman K, Blom JD, et al. Auditory verbal hallucinations in patients with borderline personality disorder are similar to those in schizophrenia. Psychol Med 2012; 16:1–6.

An interesting study comparing the characteristics of AVH in patients with schizophrenia and BPD.

6. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders. 4th ed. Washington DC: American Psychiatric Association; 1994.

7. American Psychiatric Association (APA). DSM-V Development: T 00 Borderline Personality Disorder. http://www.dsm5.org/ProposedRevision/Pages/proposedrevision.aspx?rid=17. [Accessed 13 August 2012]

8. Zanarini MC, Gunderson JG, Frankenburg FR. Cognitive features of borderline personality disorder. Am J Psychiatry 1990; 147:57–63.

9. El-Mallakh RS, Walker KL. Hallucinations, psuedohallucinations, and parahallucinations. Psychiatry 2010; 73:34–42.

10. Hagen FW. On the theory of hallucinations (in German). Allgemeine Zeitschrift fur Psychiatrie 1868; 25:1–107.

11. van der Zwaard R, Polak MA. Pseudohallucinations: a pseudoconcept? A review of the validity of the concept, related to associate symptomatology. Compr Psychiatry 2001; 42:42–50.

12. Kingdon DG, Ashcroft K, Bhandari B, et al. Schizophrenia and borderline personality disorder: similarities and differences in the experience of auditory hallucinations, paranoia, and childhood trauma. J Nerv Ment Dis 2010; 198:399–403.

13▪▪. Laroi F, Sommer IE, Blom JD, et al. The characteristic features of auditory verbal hallucinations in clinical and nonclinical groups: state-of-the-art overview and future directions. Schizophr Bull 2012; 38:724–733.

A comprehensive review of findings regarding the phenomenology of AVH in clinical and nonclinical populations.

14. Daalman K, Boks MP, Diederen KM, et al. The same or different? A phenomenological comparison of auditory verbal hallucinations in healthy and psychotic individuals. J Clin Psychiatry 2011; 72:320–325.

15. Copolov D, Trauer T, Mackinnon A. On the nonsignificance of internal versus external auditory hallucinations. Schizophr Res 2004; 69:1–6.

16. Dorahy MJ, Shannon C, Seagar L, et al. Auditory hallucinations in dissociative identity disorder and schizophrenia with and without a childhood trauma history: similarities and differences. J Nerv Ment Dis 2009; 197:892–898.

17. Brewin CR, Patel T. Auditory pseudohallucinations in United Kingdom war veterans and civilians with posttraumatic stress disorder. J Clin Psychiatry 2010; 71:419–425.

18. Daalman K, Diederen KM, Derks EM, et al. Childhood trauma and auditory verbal hallucinations. Psychol Med 2012; 16:1–10.

19▪▪. Diederen KM, Daalman K, de Weijer AD, et al. Auditory hallucinations elicit similar brain activation in psychotic and nonpsychotic individuals. Schizophr Bull 2012; 38:1074–1082.

A functional MRI study reporting similar brain activation in nonpsychotic and psychotic individuals experiencing AVH.

20. Adams B, Sanders T. Experiences of psychosis in borderline personality disorder: a qualitative analysis. J Ment Health 2011; 20:381–391.

21. Chopra HD, Beatson JA. Psychotic symptoms in borderline personality disorder. Am J Psychiatry 1986; 143:1605–1607.

22. George A, Soloff PH. Schizotypal symptoms in patients with borderline personality disorders. Am J Psychiatry 1986; 143:212–215.

23. Yee L, Korner AJ, McSwiggan S, et al. Persistent hallucinosis in borderline personality disorder. Compr Psychiatry 2005; 46:147–154.

24. Miller FT, Abrams T, Dulit R, Fyer M. Psychotic symptoms in patients with borderline personality disorder and concurrent axis I disorder. Hosp Community Psychiatry 1993; 44:59–61.

25. Nishizono-Maher A, Ikuta N, Ogiso Y, et al. Psychotic symptoms in depression and borderline personality disorder. J Affect Disord 1993; 28:279–285.

26. Suzuki H, Tsukamoto C, Nakano Y, et al. Delusions and hallucinations in patients with borderline personality disorder. Psychiatry Clin Neurosci 1998; 52:605–610.

27. Derogatis LR, Lipman RS, Covi L. SCL-90: an outpatient psychiatric rating scale – preliminary report. Psychopharmacol Bull 1973; 9:13–28.

28. Haddock G, McCarron J, Tarrier N, Faragher EB. Scales to measure dimensions of hallucinations and delusions: the psychotic symptom rating scales (PSYRATS). Psychol Med 1999; 29:879–889.

29. Coid J, Yang M, Bebbington P, et al. Borderline personality disorder: health service use and social functioning among a national household population. Psychol Med 2009; 39:1721–1731.

30. Gunderson JG, Kolb JE, Austin V. The diagnostic interview for borderline patients. Am J Psychiatry 1981; 138:896–903.

31. Zanarini MC, Gunderson JG, Frankenburg FR, Chauncey DL. The revised diagnostic interview for borderlines: discriminating BPD from other Axis II disorders. J Pers Disord 1989; 3:10–18.

32. Sbrana A, Dell’Osso L, Benvenuti A, et al. The psychotic spectrum: validity and reliability of the Structured Clinical Interview for the Psychotic Spectrum. Schizophr Res 2005; 75:375–387.

33. First MB, Gibbon M. The Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) and the Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II). In: Hilsenroth MJ, Segal DL, editors. Comprehensive handbook of psychological assessment, Personality assessment. Vol. 2. Hoboken, NJ: John Wiley & Sons Inc.; 2004. pp. 134–143.

34. Benvenuti A, Rucci P, Ravani L, et al. Psychotic features in borderline patients: is there a connection to mood dysregulation? Bipolar Disord 2005; 7:338–343.

35. Zanarini MC, Frankenburg FR, Hennen J, et al. Axis I comorbidity in patients with borderline personality disorder: 6-year follow-up and prediction of time to remission. Am J Psychiatry 2004; 161:2108–2114.

36. Bahorik AL, Eack SM. Examining the course and outcome of individuals diagnosed with schizophrenia and comorbid borderline personality disorder. Schizophr Res 2010; 124:29–35.

37. Schroeder K, Hoppe A, Andresen B, et al. Considering DSM-5: personality diagnostics in patients with schizophrenia spectrum disorders. Psychiatry 2012; 75:120–134.

38. Moran P, Walsh E, Tyrer P, et al. Does co-morbid personality disorder increase the risk of suicidal behaviour in psychosis? Acta Psychiatr Scand 2003; 107:441–448.

39. Schulz SC, Zanarini MC, Bateman A, et al. Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study. Br J Psychiatry 2008; 193:485–492.

40. Nickel MK. Aripiprazole treatment of patients with borderline personality disorder. J Clin Psychiatry 2007; 68:1815–1816.

41. Schafer I, Fisher HL. Childhood trauma and posttraumatic stress disorder in patients with psychosis: clinical challenges and emerging treatments. Curr Opin Psychiatry 2011; 24:514–518.

42. Kessler RC. The National Comorbidity Survey of the United States. Int Rev Psychiatry 1994; 6:365–376.

43. Shevlin M, Murphy J, Read J, et al. Childhood adversity and hallucinations: a community-based study using the National Comorbidity Survey Replication. Soc Psychiatry Psychiatr Epidemiol 2011; 46:1203–1210.

44. Zanarini MC. Childhood experiences associated with the development of borderline personality disorder. Psychiatr Clin North Am 2000; 23:89–101.

45. Teicher MH, Samson JA, Polcari A, McGreenery CE. Sticks, stones, and hurtful words: relative effects of various forms of childhood maltreatment. Am J Psychiatry 2006; 163:993–1000.

46. Laporte L, Paris J, Guttman H, Russell J. Psychopathology, childhood trauma, and personality traits in patients with borderline personality disorder and their sisters. J Pers Disord 2011; 25:448–462.

47. Sack M, Sachsse U, Overkamp B, Dulz B. Trauma-related disorders in patients with borderline personality disorders: Results of a multicenter study (in German). Nervenarzt 2012. [Epub ahead of print]

48. Shearer SL, Peters CP, Quaytman MS, Ogden RL. Frequency and correlates of childhood sexual and physical abuse histories in adult female borderline inpatients. Am J Psychiatry 1990; 147:214–216.

49. Zanarini MC, Williams AA, Lewis RE, et al. Reported pathological childhood experiences associated with the development of borderline personality disorder. Am J Psychiatry 1997; 154:1101–1106.

50. Glaser JP, Van Os J, Thewissen V, Myin-Germeys I. Psychotic reactivity in borderline personality disorder. Acta Psychiatr Scand 2010; 121:125–134.

51. Braakman MH, Kortmann FA, van den Brink W. Validity of ‘posttraumatic stress disorder with secondary psychotic features’: a review of the evidence. Acta Psychiatr Scand 2009; 119:15–24.

52. Shevlin M, Armour C, Murphy J, et al. Evidence for a psychotic posttraumatic stress disorder subtype based on the National Comorbidity Survey. Soc Psychiatry Psychiatr Epidemiol 2011; 46:1069–1078.

53. Mueser KT, Rosenberg SD, Goodman LA, Trumbetta SL. Trauma, PTSD, and the course of severe mental illness: an interactive model. Schizophr Res 2002; 53:123–143.

54. Zanarini MC, Frankenburg FR, Parachini EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry 2004; 65:903–907.

55. Bogenschutz MP, George Nurnberg H. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry 2004; 65:104–109.

56. Linehan MM, McDavid JD, Brown MZ, et al. Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 2008; 69:999–1005.

57. Shafti SS, Shahveisi B. Olanzapine versus haloperidol in the management of borderline personality disorder: a randomized double-blind trial. J Clin Psychopharmacol 2010; 30:44–47.

58. Soler J, Pascual JC, Campins J, et al. Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry 2005; 162:1221–1224.

59. Frankenburg FR, Zanarini MC. Clozapine treatment of borderline patients: a preliminary study. Compr Psychiatry 1993; 34:402–405.

60. Parker GF. Clozapine and borderline personality disorder. Psychiatr Serv 2002; 53:348–349.

61. Benedetti F, Sforzini L, Colombo C, et al. Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry 1998; 59:103–107.

62. Schulz SC, Camlin KL, Berry SA, Jesberger JA. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry 1999; 46:1429–1435.

63. Zanarini MC, Schulz SC, Detke H, et al. Open-label treatment with olanzapine for patients with borderline personality disorder. J Clin Psychopharmacol 2012; 32:398–402.

64. Gruettert T, Friege L. Quetiapine in patients with borderline personality disorder and psychosis: a case series. Int J Psychiatry Clin Pract 2005; 9:180–186.

65. Mauri MC, Volonteri LS, Fiorentini A, et al. Two weeks’ quetiapine treatment for schizophrenia, drug-induced psychosis and borderline personality disorder: a naturalistic study with drug plasma levels. Expert Opin Pharmacother 2007; 8:2207–2213.

66. Friedel RO, Jackson WT, Huston CS, et al. Risperidone treatment of borderline personality disorder assessed by a borderline personality disorder-specific outcome measure: a pilot study. J Clin Psychopharmacol 2008; 28:345–347.

67. Bellino S, Bozzatello P, Rinaldi C, Bogetto F. Paliperidone ER in the treatment of borderline personality disorder: a pilot study of efficacy and tolerability. Depress Res Treat 2011. [Epub ahead of print]

68. Nickel MK, Loew TH, Pedrosa Gil F. Aripiprazole in treatment of borderline patients, part II: an 18-month follow-up. Psychopharmacology (Berl) 2007; 191:1023–1026.

69. Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of aripiprazole augmentation in sertraline-resistant patients with borderline personality disorder. Psychiatry Res 2008; 161:206–212.

70. Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 2001; 62:849–854.

71. Zanarini MC, Schulz SC, Detke HC, et al. A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2011; 72:1353–1362.

72. Zanarini MC, Vujanovic AA, Parachini EA, et al. Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD): a continuous measure of DSM-IV borderline psychopathology. J Pers Disord 2003; 17:233–242.

73. Nickel MK, Muehlbacher M, Nickel C, et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2006; 163:833–838.

74. Derogatis LR, Melisaratos N. The Brief Symptom Inventory: an introductory report. Psychol Med 1983; 13:595–605.

75. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962; 10:799–812.

76. Pascual JC, Soler J, Puigdemont D, et al. Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study. J Clin Psychiatry 2008; 69:603–608.

77. Soloff P. Special feature: psychobiologic perspectives on treatment of personality disorders. J Pers Disord 1997; 11:336–344.

78. Laddis A. Outcome of crisis intervention for borderline personality disorder and post traumatic stress disorder: a model for modification of the mechanism of disorder in complex post traumatic syndromes. Ann Gen Psychiatry 2010; 9:1–12.

79. American Psychiatric Association (APA). Practice guideline for the treatment of patients with borderline personality disorder. Am J Psychiatry 2001; 158(Suppl 10):1–52.

80. Therien P, Tranulis C, Lecomte T, Berube F-A. The experience of treatment of persons with concomitant psychotic and borderline personality disorders. Psychosis 2012; 4:63–73.

81. Gleeson JF, Chanen A, Cotton SM, et al. Treating co-occurring first-episode psychosis and borderline personality: a pilot randomized controlled trial. Early Interv Psychiatry 2012; 6:21–29.

82. Chanen AM, McCutcheon LK, Germano D, et al. The HYPE Clinic: an early intervention service for borderline personality disorder. J Psychiatr Pract 2009; 15:163–172.

83▪. Hepworth CR, Ashcroft K, Kingdon D. Auditory Hallucinations: A Comparison of Beliefs about Voices in Individuals with Schizophrenia and Borderline Personality Disorder. Clin Psychol Psychother 2011. [Epub ahead of print]

Another recent study on the characteristics of psychotic symptoms in patients with schizophrenia compared with those in BPD patients, including also a group of patients with both diagnoses.

© 2013 Lippincott Williams & Wilkins, Inc.

Source: Psychotic symptoms in patients with borderline personality d… : Current Opinion in Psychiatry

Comments are closed.
%d bloggers like this: